ATE181919T1 - Camptothecinderivat und dessen verwendung als antitumormittel - Google Patents
Camptothecinderivat und dessen verwendung als antitumormittelInfo
- Publication number
- ATE181919T1 ATE181919T1 AT96105661T AT96105661T ATE181919T1 AT E181919 T1 ATE181919 T1 AT E181919T1 AT 96105661 T AT96105661 T AT 96105661T AT 96105661 T AT96105661 T AT 96105661T AT E181919 T1 ATE181919 T1 AT E181919T1
- Authority
- AT
- Austria
- Prior art keywords
- compound
- tumor agent
- formula
- target
- camptothecine
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8371795 | 1995-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE181919T1 true ATE181919T1 (de) | 1999-07-15 |
Family
ID=13810270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96105661T ATE181919T1 (de) | 1995-04-10 | 1996-04-10 | Camptothecinderivat und dessen verwendung als antitumormittel |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6504029B1 (de) |
| EP (1) | EP0737686B1 (de) |
| KR (1) | KR100400941B1 (de) |
| CN (1) | CN1050131C (de) |
| AT (1) | ATE181919T1 (de) |
| CA (1) | CA2173671A1 (de) |
| DE (1) | DE69603117T2 (de) |
| DK (1) | DK0737686T3 (de) |
| EA (1) | EA000036B1 (de) |
| ES (1) | ES2136338T3 (de) |
| GR (1) | GR3031400T3 (de) |
| NO (1) | NO314085B1 (de) |
| TW (1) | TW382630B (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2401191C (en) | 2000-02-28 | 2006-05-02 | Aventis Pharma S.A. | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| US6548488B2 (en) | 2000-03-17 | 2003-04-15 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| AR030207A1 (es) * | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| US6486320B2 (en) | 2000-09-15 | 2002-11-26 | Aventis Pharma S.A. | Preparation of camptothecin and of its derivatives |
| AU1602902A (en) | 2000-10-27 | 2002-05-06 | Aventis Pharma Sa | A combination comprising camptothecin and a stilbene derivative for the treatment of cancer |
| WO2012050591A1 (en) | 2010-10-15 | 2012-04-19 | Rutgers, The State University Of New Jersey | Hydrogel formulation for dermal and ocular delivery |
| US20090104254A1 (en) | 2004-12-22 | 2009-04-23 | Rutgers, The State University Of New Jersey | Controlled Release Hydrogels |
| AU2007232206B2 (en) | 2006-03-30 | 2013-04-04 | Drais Pharmaceuticals, Inc. | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
| SG184324A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| EP3130608B1 (de) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2-antikörper)-arzneimittelkonjugat |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| US11273155B2 (en) | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| JP6679762B2 (ja) | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| CA3074208C (en) * | 2017-08-31 | 2023-10-03 | Daiichi Sankyo Company, Limited | Novel method for producing antibody-drug conjugate |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| WO2020022475A1 (ja) | 2018-07-27 | 2020-01-30 | 第一三共株式会社 | 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質 |
| CA3108044A1 (en) | 2018-07-31 | 2020-02-06 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| WO2020063676A1 (zh) | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CA3114474A1 (en) | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| MX2021011812A (es) | 2019-03-29 | 2021-10-22 | Medimmune Ltd | Compuestos y conjugados de estos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US20230054458A1 (en) | 2019-12-12 | 2023-02-23 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| JP7781064B2 (ja) | 2020-01-22 | 2025-12-05 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途 |
| CN115103858B (zh) | 2020-03-25 | 2025-07-15 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| MX2022011808A (es) | 2020-03-25 | 2022-12-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Conjugado de anticuerpo anti-psma-analogo de exatecan y uso medico del mismo. |
| BR112022019073A2 (pt) | 2020-03-25 | 2022-11-08 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma |
| US20240376120A1 (en) * | 2021-09-01 | 2024-11-14 | Shanghai Best-Link Bioscience, Llc | Camptothecin compound, preparation method therefor and use thereof |
| CN117986268A (zh) * | 2022-10-28 | 2024-05-07 | 安徽皓元药业有限公司 | 一种依喜替康甲磺酸盐的晶型及其制备方法 |
| JP2026503204A (ja) * | 2023-01-09 | 2026-01-28 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 窒素含有縮合環化合物の調製方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6087746A (ja) * | 1983-10-17 | 1985-05-17 | Hakubakumai Kk | 即席麺ないしは焼そば用蒸し麺の製造方法 |
| US4939255A (en) * | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| US5658920A (en) * | 1991-01-16 | 1997-08-19 | Daiichi Pharmaceutical Co., Ltd. | Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound |
| JP3008226B2 (ja) * | 1991-01-16 | 2000-02-14 | 第一製薬株式会社 | 六環性化合物 |
| JP3359955B2 (ja) * | 1992-07-16 | 2002-12-24 | 第一製薬株式会社 | 抗腫瘍剤 |
| IS4152A (is) * | 1993-04-29 | 1994-10-30 | Glaxo Inc. | Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra |
| GB9319944D0 (en) * | 1993-09-28 | 1993-11-17 | Erba Carlo Spa | Process for the preparation of 9-amino camptothecin |
-
1995
- 1995-07-13 US US08/501,933 patent/US6504029B1/en not_active Expired - Fee Related
- 1995-09-18 CN CN95116111A patent/CN1050131C/zh not_active Expired - Fee Related
-
1996
- 1996-04-04 KR KR1019960010291A patent/KR100400941B1/ko not_active Expired - Fee Related
- 1996-04-09 NO NO19961405A patent/NO314085B1/no unknown
- 1996-04-09 CA CA002173671A patent/CA2173671A1/en not_active Abandoned
- 1996-04-09 TW TW085104156A patent/TW382630B/zh not_active IP Right Cessation
- 1996-04-09 EA EA199600018A patent/EA000036B1/ru not_active IP Right Cessation
- 1996-04-10 ES ES96105661T patent/ES2136338T3/es not_active Expired - Lifetime
- 1996-04-10 DE DE69603117T patent/DE69603117T2/de not_active Expired - Fee Related
- 1996-04-10 AT AT96105661T patent/ATE181919T1/de not_active IP Right Cessation
- 1996-04-10 EP EP96105661A patent/EP0737686B1/de not_active Expired - Lifetime
- 1996-04-10 DK DK96105661T patent/DK0737686T3/da active
-
1999
- 1999-09-30 GR GR990402491T patent/GR3031400T3/el unknown
-
2001
- 2001-06-11 US US09/876,945 patent/US6552197B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK0737686T3 (da) | 1999-11-22 |
| EA000036B1 (ru) | 1998-02-26 |
| CN1050131C (zh) | 2000-03-08 |
| CN1133290A (zh) | 1996-10-16 |
| EA199600018A3 (ru) | 1997-03-31 |
| US6552197B2 (en) | 2003-04-22 |
| GR3031400T3 (en) | 2000-01-31 |
| KR100400941B1 (ko) | 2003-12-24 |
| NO961405L (no) | 1996-10-11 |
| AU5056696A (en) | 1996-10-24 |
| CA2173671A1 (en) | 1996-10-11 |
| ES2136338T3 (es) | 1999-11-16 |
| NO961405D0 (no) | 1996-04-09 |
| EA199600018A2 (ru) | 1996-10-01 |
| DE69603117T2 (de) | 1999-10-28 |
| US20010034446A1 (en) | 2001-10-25 |
| NO314085B1 (no) | 2003-01-27 |
| AU692078B2 (en) | 1998-05-28 |
| EP0737686A1 (de) | 1996-10-16 |
| KR960037682A (ko) | 1996-11-19 |
| TW382630B (en) | 2000-02-21 |
| DE69603117D1 (de) | 1999-08-12 |
| EP0737686B1 (de) | 1999-07-07 |
| US6504029B1 (en) | 2003-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE181919T1 (de) | Camptothecinderivat und dessen verwendung als antitumormittel | |
| HU9600962D0 (en) | Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| DE3378763D1 (en) | Condensed pyrrolinone derivatives, and their production | |
| TW240249B (de) | ||
| NO882588L (no) | Fremgangsmaate ved fremstilling av substituerte inololinonderivater. | |
| FI873380A0 (fi) | Foerfarande foer framstaellning av kinolinkarboxylsyror. | |
| ATE37872T1 (de) | Phenylinden-derivate, ihre salze, und verfahren zu ihrer herstellung. | |
| EA199900528A1 (ru) | Новые производные эритромицина, способ их получения и применения в качетве медикаментов | |
| DE69809888D1 (de) | Verfahren zur Herstellung von alpha-Aminoketonen | |
| ES2193524T3 (es) | Procedimiento de preparacion de acido azetidino-2-carboxilico. | |
| DE59406746D1 (de) | Verfahren zur herstellung von schwefelsäurehalbestern | |
| DK159432C (da) | Fremgangsmaade til fremstilling af 4-amino-5-dialkoxymethylpyrimidinderivater | |
| ATE159519T1 (de) | Verfahren zur herstellung von n-phenyl-n-(4- piperidinyl)amid-derivaten | |
| RU94037966A (ru) | Карбоксамидные соединения, способ получения карбоксамидных соединений, промежуточные соединения и способы их получения | |
| FR2552430B1 (fr) | Procede de preparation de quinolinones-4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEIH | Change in the person of patent owner | ||
| REN | Ceased due to non-payment of the annual fee |